Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model

BACKGROUND: Tyrosine kinases are attractive targets for pancreatic cancer therapy because several are over-expressed, including PDGFRα/β, FAK, Src and Lyn. A critical role of mast cells in the development of pancreatic cancer has also been reported. Masitinib is a tyrosine kinase inhibitor that sele...

Descripción completa

Detalles Bibliográficos
Autores principales: Humbert, Martine, Castéran, Nathalie, Letard, Sébastien, Hanssens, Katia, Iovanna, Juan, Finetti, Pascal, Bertucci, François, Bader, Thomas, Mansfield, Colin D., Moussy, Alain, Hermine, Olivier, Dubreuil, Patrice
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832006/
https://www.ncbi.nlm.nih.gov/pubmed/20209107
http://dx.doi.org/10.1371/journal.pone.0009430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832006/
https://www.ncbi.nlm.nih.gov/pubmed/20209107
http://dx.doi.org/10.1371/journal.pone.0009430

Ejemplares similares